An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia

Alok Swaroop, Jon A. Oyer, Christine M. Will, Xiaoxiao Huang, Wenbo Yu, Catalina Troche, Marinka Bulic, Benjamin H. Durham, Qiang Jeremy Wen, John D. Crispino, Alexander D. MacKerell, Richard L. Bennett, Neil L. Kelleher, Jonathan D. Licht*

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

NSD2, a histone methyltransferase specific for methylation of histone 3 lysine 36 (H3K36), exhibits a glutamic acid to lysine mutation at residue 1099 (E1099K) in childhood acute lymphocytic leukemia (ALL), and cells harboring this mutation can become the predominant clone in relapsing disease. We studied the effects of this mutant enzyme in silico, in vitro, and in vivo using gene edited cell lines. The E1099K mutation altered enzyme/substrate binding and enhanced the rate of H3K36 methylation. As a result, cell lines harboring E1099K exhibit increased H3K36 dimethylation and reduced H3K27 trimethylation, particularly on nucleosomes containing histone H3.1. Mutant NSD2 cells exhibit reduced apoptosis and enhanced proliferation, clonogenicity, adhesion, and migration. In mouse xenografts, mutant NSD2 cells are more lethal and brain invasive than wildtype cells. Transcriptional profiling demonstrates that mutant NSD2 aberrantly activates factors commonly associated with neural and stromal lineages in addition to signaling and adhesion genes. Identification of these pathways provides new avenues for therapeutic interventions in NSD2 dysregulated malignancies.

Original languageEnglish (US)
Pages (from-to)671-686
Number of pages16
JournalOncogene
Volume38
Issue number5
DOIs
StatePublished - Jan 31 2019

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutation
Histones
Methylation
Lysine
Cell Line
Nucleosomes
Enzymes
Heterografts
Computer Simulation
Genes
Glutamic Acid
Clone Cells
Apoptosis
histone methyltransferase
Brain
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Swaroop, A., Oyer, J. A., Will, C. M., Huang, X., Yu, W., Troche, C., ... Licht, J. D. (2019). An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. Oncogene, 38(5), 671-686. https://doi.org/10.1038/s41388-018-0474-y
Swaroop, Alok ; Oyer, Jon A. ; Will, Christine M. ; Huang, Xiaoxiao ; Yu, Wenbo ; Troche, Catalina ; Bulic, Marinka ; Durham, Benjamin H. ; Wen, Qiang Jeremy ; Crispino, John D. ; MacKerell, Alexander D. ; Bennett, Richard L. ; Kelleher, Neil L. ; Licht, Jonathan D. / An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. In: Oncogene. 2019 ; Vol. 38, No. 5. pp. 671-686.
@article{f5b7509bfd334106985efe603719dc03,
title = "An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia",
abstract = "NSD2, a histone methyltransferase specific for methylation of histone 3 lysine 36 (H3K36), exhibits a glutamic acid to lysine mutation at residue 1099 (E1099K) in childhood acute lymphocytic leukemia (ALL), and cells harboring this mutation can become the predominant clone in relapsing disease. We studied the effects of this mutant enzyme in silico, in vitro, and in vivo using gene edited cell lines. The E1099K mutation altered enzyme/substrate binding and enhanced the rate of H3K36 methylation. As a result, cell lines harboring E1099K exhibit increased H3K36 dimethylation and reduced H3K27 trimethylation, particularly on nucleosomes containing histone H3.1. Mutant NSD2 cells exhibit reduced apoptosis and enhanced proliferation, clonogenicity, adhesion, and migration. In mouse xenografts, mutant NSD2 cells are more lethal and brain invasive than wildtype cells. Transcriptional profiling demonstrates that mutant NSD2 aberrantly activates factors commonly associated with neural and stromal lineages in addition to signaling and adhesion genes. Identification of these pathways provides new avenues for therapeutic interventions in NSD2 dysregulated malignancies.",
author = "Alok Swaroop and Oyer, {Jon A.} and Will, {Christine M.} and Xiaoxiao Huang and Wenbo Yu and Catalina Troche and Marinka Bulic and Durham, {Benjamin H.} and Wen, {Qiang Jeremy} and Crispino, {John D.} and MacKerell, {Alexander D.} and Bennett, {Richard L.} and Kelleher, {Neil L.} and Licht, {Jonathan D.}",
year = "2019",
month = "1",
day = "31",
doi = "10.1038/s41388-018-0474-y",
language = "English (US)",
volume = "38",
pages = "671--686",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "5",

}

Swaroop, A, Oyer, JA, Will, CM, Huang, X, Yu, W, Troche, C, Bulic, M, Durham, BH, Wen, QJ, Crispino, JD, MacKerell, AD, Bennett, RL, Kelleher, NL & Licht, JD 2019, 'An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia', Oncogene, vol. 38, no. 5, pp. 671-686. https://doi.org/10.1038/s41388-018-0474-y

An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. / Swaroop, Alok; Oyer, Jon A.; Will, Christine M.; Huang, Xiaoxiao; Yu, Wenbo; Troche, Catalina; Bulic, Marinka; Durham, Benjamin H.; Wen, Qiang Jeremy; Crispino, John D.; MacKerell, Alexander D.; Bennett, Richard L.; Kelleher, Neil L.; Licht, Jonathan D.

In: Oncogene, Vol. 38, No. 5, 31.01.2019, p. 671-686.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia

AU - Swaroop, Alok

AU - Oyer, Jon A.

AU - Will, Christine M.

AU - Huang, Xiaoxiao

AU - Yu, Wenbo

AU - Troche, Catalina

AU - Bulic, Marinka

AU - Durham, Benjamin H.

AU - Wen, Qiang Jeremy

AU - Crispino, John D.

AU - MacKerell, Alexander D.

AU - Bennett, Richard L.

AU - Kelleher, Neil L.

AU - Licht, Jonathan D.

PY - 2019/1/31

Y1 - 2019/1/31

N2 - NSD2, a histone methyltransferase specific for methylation of histone 3 lysine 36 (H3K36), exhibits a glutamic acid to lysine mutation at residue 1099 (E1099K) in childhood acute lymphocytic leukemia (ALL), and cells harboring this mutation can become the predominant clone in relapsing disease. We studied the effects of this mutant enzyme in silico, in vitro, and in vivo using gene edited cell lines. The E1099K mutation altered enzyme/substrate binding and enhanced the rate of H3K36 methylation. As a result, cell lines harboring E1099K exhibit increased H3K36 dimethylation and reduced H3K27 trimethylation, particularly on nucleosomes containing histone H3.1. Mutant NSD2 cells exhibit reduced apoptosis and enhanced proliferation, clonogenicity, adhesion, and migration. In mouse xenografts, mutant NSD2 cells are more lethal and brain invasive than wildtype cells. Transcriptional profiling demonstrates that mutant NSD2 aberrantly activates factors commonly associated with neural and stromal lineages in addition to signaling and adhesion genes. Identification of these pathways provides new avenues for therapeutic interventions in NSD2 dysregulated malignancies.

AB - NSD2, a histone methyltransferase specific for methylation of histone 3 lysine 36 (H3K36), exhibits a glutamic acid to lysine mutation at residue 1099 (E1099K) in childhood acute lymphocytic leukemia (ALL), and cells harboring this mutation can become the predominant clone in relapsing disease. We studied the effects of this mutant enzyme in silico, in vitro, and in vivo using gene edited cell lines. The E1099K mutation altered enzyme/substrate binding and enhanced the rate of H3K36 methylation. As a result, cell lines harboring E1099K exhibit increased H3K36 dimethylation and reduced H3K27 trimethylation, particularly on nucleosomes containing histone H3.1. Mutant NSD2 cells exhibit reduced apoptosis and enhanced proliferation, clonogenicity, adhesion, and migration. In mouse xenografts, mutant NSD2 cells are more lethal and brain invasive than wildtype cells. Transcriptional profiling demonstrates that mutant NSD2 aberrantly activates factors commonly associated with neural and stromal lineages in addition to signaling and adhesion genes. Identification of these pathways provides new avenues for therapeutic interventions in NSD2 dysregulated malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85053332812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053332812&partnerID=8YFLogxK

U2 - 10.1038/s41388-018-0474-y

DO - 10.1038/s41388-018-0474-y

M3 - Article

C2 - 30171259

AN - SCOPUS:85053332812

VL - 38

SP - 671

EP - 686

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 5

ER -